Home  >  Products  >  Fibrinogen BioAssay(TM) ELISA Kit (Antibodies only)

Fibrinogen BioAssay(TM) ELISA Kit (Antibodies only)

Cat no: F4202


Supplier: United States Biological
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
Fibrinogen is an abundant plasma protein (5-10uM) produced in the liver. The intact protein has a MW of 340kD. It is composed of 3 pairs of disulfide-bound polypeptide chains named Aalpha, Bbeta and gamma. Fibrinogen is a triglobular protein consisting of a central E domain and terminal D domains. Proteolysis by thrombin results in release of Fibrinopeptide A (FPA, Aalpha1-16) followed by Fibrinopeptide B (FPB, Bbeta1-14) and the fibrin monomers that result polymerize in a half-overlap fashion to form insoluble fibrin fibrils. The chains of fibrin are referred to as alpha, beta and gamma, due to the removal of FPA and FPB. The polymerized fibrin is subsequently stabilized by the transglutaminase activated Factor XIII that forms amide linkages between gamma chains and, to a lesser extent, alpha chains of the fibrin molecules. Proteolysis of fibrinogen by plasmin initially liberates C-terminal residues from the A-alpha chain to produce fragment X (intact D-E-D, which is still clottable). Fragment X is further degraded to non-clottable fragments Y (D-E) and D. Fragment Y can be digested into its constituent D and E fragments. Digestion of non-crosslinked fibrin with plasmin is very similar to the digestion of fibrinogen, which results in production of fragments D and E. Degradation of crosslinked fibrin by plasmin results in fragment DD (D-Dimer consisting of the D domains of 2 fibrin molecules crosslinked via the gamma chains), fragment E (central E domain) as well as DDE in which fragment E is non-covalently associated with DD. For human crosslinked fibrin, the relative weights of the cleavage fragments produced are: 184kD for fragment DD, 92kD for D, 50kD for E, 1.54kD for FPA and 1.57kD for FPB1-3. Principle of the Assay: Affinity-purified polyclonal antibody to Fg is coated onto the wells of a microtiter plate. Any remaining binding sites on the plastic wells are blocked with bovine serum albumin. The plates are washed and plasma or other fluids containing Fg are applied. The coated antibody will capture the Fg in the sample. After washing the plate to remove unbound material, a peroxidase conjugated second antibody to Fg is added to the plate to bind to the captured Fg. After washing the plate to remove unbound conjugated antibody, the peroxidase activity is expressed by incubation with ophenylenediamine (OPD). After a fixed development time the reaction is quenched with the addition of H2SO4 and the color produced is quantified using a microplate reader. The color generated is proportional to the concentration of Fg in the sample. Qauntity: Sufficient reagent for 5x96 well plates Kit Components: F4202A: Capture Antibody, 1x500ul Affinity-purified sheep anti-Fg IgG suitable for coating ELISA plates. F4202B: Detection Antibody (HRP), 1x500ul Affinity-purified sheep anti-Fg labeled with HRP suitable for detection of Fg. Storage and Stability: May be stored at 4 degrees C for short-term only. For long-term storage, store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Catalogue number: F4202
Reactivities: Human
Applications: ELISA
Size: 1Kit
Form: Supplied as a liquid in buffer, 50% glycerol.
Purity: Purified by affinity chromotography.
References: 1. Hantgan, R.R., Francis, C.W., Marder, V.J.: Fibrinogen Structure and Physiology; in Hemostasis and Thrombosis, 3rd Edition, eds. R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman, pp 277-300, J.B. Lippincott Co., Philadelphia PA, USA, 1994. 2. Butler, J.E., et al., Federation Proceedings 46(8): 2548-2556 (1987). 3. Harlow, E., Lane, D.: Detecting and Quantitating Antigens using the Two-Antibody Sandwich Assay, in Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, p 580, 1988. 4. Shafer, J.A., Higgins, D.L.: Human Fibrinogen; CRC Critical Reviews in Clinical Laboratory Sciences 26, pp 1-41, 1988. 5. Binnie, C.G. and Lord, S.T., Blood 81: 3186-3192 (1993). 6. Nix, B., Wild, D.: in Immunoassays, A Practical Approach, editor J.P. Gosling, pp. 239-261, Oxford University Press, 2000. 7. NCCLS. Evaluation of the Linearity of Quantitative Analytical Methods; Proposed Guidline. Second Edition. NCCLS Document EP6-P2 (ISBN 1-56238-446-5, NCCLS, Wayne, Pennsylvania USA (2001). 8. Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline-Third Edition. NCCLS Document H21-A#, VOl18, No. 20, NCCLS Wayne, Pennsylvania USA (1998). 9. FDA Guidance for Industry. Bioanalytical Method Validation (May 2001). available on the internet: www.fda.gov/cder/guidance/index.htm.
Additional info: Recognizes human Fibrinogen.

Get Quote

  • Best Price Guaranteed
  • Quick Response Time
  • Exclusive Promotions
Enquiry_down_arrow
United States Biological
Get a Quote Direct from
United States Biological

By submitting this form you agree to your details being passed to United States Biological for the purpose of generating the best quote*

Button_on Button_off_biosave Button_off_biosave Button_off_biosave Button_off_biosave Button_off_biosave Button_off_biosave